SCOPUS 정보 검색 플랫폼

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 199-202

Back to the future: Driving innovation in drug development

(1) Wagner, J A a

a MERCK RESEARCH LABORATORIES (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIGITALIS;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; DRUG DESIGN; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; DIFFUSION OF INNOVATION; DIGITALIS GLYCOSIDES; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG INDUSTRY; HISTORY, 18TH CENTURY; MODELS, BIOLOGICAL; RESEARCH DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 38349141917 PISSN: 00099236 EISSN: 15326535 Source Type: Journal
DOI: 10.1038/sj.clpt.6100477 Document Type: Editorial

Times cited : (7)

References (9)

1
- 38349090575
- The state of innovation in drug development
- Kola, I. The state of innovation in drug development. Clin. Pharmacol. Ther. 83, 227-230 (2008).
- (2008) Clin. Pharmacol. Ther , vol.83 , pp. 227-230
- Kola, I.¹

2
- 38349144393
- Obstacles and opportunities in new drug development
- Kaitin, K.I. Obstacles and opportunities in new drug development. Clin. Pharmacol. Ther. 83, 210-212 (2008).
- (2008) Clin. Pharmacol. Ther , vol.83 , pp. 210-212
- Kaitin, K.I.¹

3
- 0031003468
- Learning versus confirming in clinical drug development
- Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
- (1997) Clin. Pharmacol. Ther , vol.61 , pp. 275-291
- Sheiner, L.B.¹

4
- 2542641907
- and Drug Administration, U.S. Department of Health and Human Services, FDA, Rockville, MD, March
- US Food and Drug Administration. Innovation/ Stagnation: Challenges and Opportunities on the Critical Path to New Medical Products (U.S. Department of Health and Human Services, FDA, Rockville, MD, March 2004).
- (2004) Innovation/ Stagnation: Challenges and Opportunities on the Critical Path to New Medical Products
- Food, U.S.¹

5
- 38349084098
- European Medicines Agency (EMEA). The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future (European Medicines Agency, London, 4 March 2005).
- European Medicines Agency (EMEA). The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future (European Medicines Agency, London, 4 March 2005).

6
- 38349095115
- Innovative early development regulatory approaches: ExpIND, expCTA, microdosing
- Robinson, W.T. Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin. Pharmacol. Ther. 83, 358-360 (2008).
- (2008) Clin. Pharmacol. Ther , vol.83 , pp. 358-360
- Robinson, W.T.¹

7
- 38349160711
- The Biomarkers Consortium: On the critical path of drug discovery
- Biomarkers Consortium
- Biomarkers Consortium, Altar, C.A. The Biomarkers Consortium: on the critical path of drug discovery. Clin. Pharmacol. Ther. 83, 361-364 (2008).
- (2008) Clin. Pharmacol. Ther , vol.83 , pp. 361-364
- Altar, C.A.¹

8
- 38349123859
- Strategic approach to fit-for-purpose biomarkers in drug development
- e-pub ahead of print 15 October
- Wagner, J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol.; e-pub ahead of print (15 October 2007).
- (2007) Annu. Rev. Pharmacol. Toxicol
- Wagner, J.A.¹

9
- 34447564991
- Pharmacometrics and the transition to model-based development
- Grasela, T.H. et al. Pharmacometrics and the transition to model-based development. Clin. Pharmacol. Ther. 82, 137-142 (2007).
- (2007) Clin. Pharmacol. Ther , vol.82 , pp. 137-142
- Grasela, T.H.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.